The Latest: Europe agency give guidance to tweak vaccines

Thursday, February 25, 2021 | The Associated Press

European Council President Charles Michel prepares to take part in an EU Summit, via videoconference link, at the European Council building in Brussels, Thursday, Feb. 25, 2021. European Union leaders are gathering Thursday, via videoconference link, to try to inject new energy into the 27-nation bloc's lagging coronavirus vaccination effort as concern mounts that new variants might spread faster than authorities can adapt. (Olivier Hoslet, Pool via AP)

BERLIN — The European Medicines Agency has issued guidance to pharmaceutical companies on how to tweak already authorized coronavirus vaccines so they can be used to immunize against new variants.

The EU regulator say the three authorized vaccines, made by Pfizer, Moderna and AstraZeneca, protect against the variants currently prevalent across Europe. However, as new mutations spread, the shots may need to be adapted.

EMA says its experts worked on the assumption the adjusted vaccine would work in the same way as the original shot, except for a change to the part that triggers the body’s immune response.

It says “large-scale safety and efficacy studies are not needed” but at least one clinical trial is recommended in people who have neither been vaccinated nor infected with the coronavirus.

The agency also suggested a study involving a small group randomly selected to receive either the parent or the variant vaccine to ensure they both trigger similar immune responses.

It says studies into using tweaked vaccines as a booster shot protecting against variants should be conducted, and it expects manufacturers to provide data on the production quality of the adjusted vaccines.



Pfizer is studying effects of third vaccine dose as booster. Dr. Fauci says take whatever vaccine is available. Drug companies can tweak vaccines to adapt to variants, a process that should be easier than coming up with the original shots. China approves two more virus vaccines for wider use to reach four total vaccines. Medical oxygen scarce for coronavirus patients in Africa, Latin America.

— Follow all of AP’s pandemic coverage at, and



MADISON, Wis. — The number of people eligible for the coronavirus vaccine in Wisconsin will increase to 700,000, including teachers and child care workers, starting Monday.

The state Department of Health Services says other eligible people will include those enrolled in Medicaid long-term care programs; grocery store workers; bus drivers; 911 dispatchers; non-essential health care workers; and staff in shared housing situations such as condominiums, student dorms and prisons.

State health officials estimate that teachers and child care workers will take priority in March and early April, while the others will be vaccinated in April and May.


LISBON, Portugal — Portugal’s parliament has approved a request from the country’s president to extend a state of emergency by another two weeks.

Portugal’s recent pandemic surge, which made it the world’s worst affected country by size of population, has receded since the lockdown was introduced on Jan. 15. Authorities are wary of ending restrictions too quickly and are keeping the lockdown through March 16.

The proposal says the lockdown must be eased in phases based on recommendations by health experts and must be accompanied by more tests and tracing.

“There’s still a long way to go,” Health Minister Marta Temido told lawmakers.

Portugal’s 14-day case rate per 100,000 inhabitants stands at 287, according to the European Centre for Disease Control. That places it 13th in the 30 countries monitored by the EU agency.


FREETOWN, Sierra Leone — Sierra Leone and Mozambique are the latest African countries to receive Sinopharm vaccines from China.

A delivery of 200,000 doses of the vaccine arrived on a chartered flight from China in Sierra Leone on Thursday. China donated the shipment of doses to the West African country. Sierra Leone, with a population of about 8 million, will need several million more vaccine doses to reach herd immunity.

In southern Africa, Mozambique’s President Filipe Nyusi announced in a post on Facebook that a shipment of vaccines had arrived from China on Wednesday. The 200,000 doses from Sinopharm are the first to arrive in Mozambique, a country of 31 million people.

Nyusi says he’d been in communication with Chinese President Xi Jinping for two months to secure the vaccines. The arrival of the Sinopharm shipment came after Mozambique learned the arrival of 2.4 million doses from the COVAX initiative won’t arrive until May, according to the state-owned Jornal Noticias.


SARAJEVO, Bosnia-Herzegovina — Bosnia says it will sue the World Health Organization’s COVAX program if it doesn’t deliver vaccines against the coronavirus as planned.

Milorad Dodik, a member of Bosnia’s multi-ethnic presidency, says the Balkan nation has done all the preparations for the arrival of the 1.2 million shots via COVAX and expects the delivery.

“Bosnia-Herzegovina is demanding that COVAX starts delivering as soon as possible,” Dodik said. “If they break the deadline, Bosnia-Herzegovina will sue the program. “

Officials with COVAX, the program designed for poorer countries, have said the promised batch of the vaccines haven’t been dispatched because Bosnia’s authorities haven’t met Pfizer’s ultra-cold storage requirements.

Bosnian officials have denied this, insisting the country has the technical capabilities to accept the vaccines.


LONDON — Health officials in Britain say the country’s COVID-19 alert level should move down from the highest level because hospitalizations have decreased.

The U.K.’s four chief medical officers say although health services remain under significant pressure, the national alert level can move from five to four because the numbers of patients in hospital are “consistently declining.”

The coronavirus alert level was raised to the highest in early January when a third national lockdown was announced amid skyrocketing cases and hospital admissions. But the spread of infection has slowed down since, partly because of Britain’s vaccination program.

More than 18 million people in the U.K. have received at least one vaccine dose, and research suggests the vaccine rollout is having significant impact on stopping serious illness.

Britain has registered 4.1 million coronavirus cases, fourth highest in the world. It’s reported more than 122,000 deaths, the fifth highest behind the U.S., Brazil, Mexico and India.


HARTFORD, Conn. — A coalition of advocacy groups for people with disabilities has filed a federal complaint alleging Connecticut’s revised age-based policy for coronavirus vaccinations discriminates against people with underlying medical conditions, including those with disabilities.

Disability Rights Connecticut announced Thursday that it filed the complaint with the Office for Civil Rights at the U.S. Department of Health and Human Services, asking the agency to order state officials to immediately revise the vaccination policy to include people with underlying medical conditions.

Democratic Gov. Ned Lamont announced a major change in the state’s vaccination schedule Monday, saying Connecticut would continue to follow a mostly age-based system after previously saying people with underlying medical conditions would be among the next group eligible for vaccinations. The only exception in the new policy is public school employees.


PHOENIX — Arizona reported 929 coronavirus cases on Thursday, the first day since Nov. 30 the state Department of Health Services reported fewer than 1,000 cases.

The latest figures increased Arizona’s total to 812,907 confirmed cases. With 121 more deaths, the state has registered 15,814 confirmed deaths.

There were 1,385 COVD-19 patients on Wednesday, down from the pandemic high of 5,082 on Jan. 11.

The rolling average of daily new cases in Arizona dropped from 3,123 on Feb. 10 to 1,559 on Wednesday. The rolling average of daily deaths dropped from 126 to 105 during the same period.


COLOMBO, Sri Lanka — Sri Lanka has received 500,000 doses of the AstraZeneca vaccine from India.

This is the first set of vaccines purchased directly by the Sri Lankan government from the Serum Institute of India. AstraZeneca is the only vaccine approved by the regulatory body in Sri Lanka.

Previously, Sri Lanka received 500,000 doses of the same vaccine as a donation from the Indian government.

Sri Lanka recently announced plans to vaccinate 14 million of its 22 million population.

The government says it plans to purchase 10 million doses AstraZeneca vaccines for $52.5 million as a direct procurement from the Serum Institute and buy 3.5 million doses from the AstraZeneca Institute in Britain.

Sri Lankan began its COVID-19 inoculation drive in January, reaching more than 370,000 persons.

Vaccination comes as Sri Lanka is experiencing a spike of the COVID-19 patients, mostly in the capital Colombo.

Sri Lanka has registered 81,467 total cases and 457 confirmed deaths.


ISTANBUL -- Turkey’s health minister says the country aims to vaccinate most citizens above the age of 20 by the end of May.

Fahrettin Koca says the country is securing 105 million doses of COVID-19 vaccines to inoculate 52.5 million people. He says Turkey has struck a deal for 100 million doses of CoronaVac, produced by the Chinese biopharmaceutical company Sinovac.

Some 6.6 million people received the first dose and about 1.5 million got the second dose since vaccinations with CoronaVac began in January. Turkey’s population is more than 83.5 million.


TAIPEI, Taiwan — China has approved two more COVID-19 vaccines for wider use, adding to its growing arsenal of shots.

It gave conditional approval to a vaccine from CanSino Biologics and one from state-owned Sinopharm. Both are already used among select groups of people under an emergency use authorization. China now has four vaccines to immunize its population of 1.3 billion people.

CanSino’s COVID-19 vaccine is the first developed by a Chinese company that requires only one shot. Both vaccines can be stored between 2 and 8 degrees Celsius.

CanSino says its vaccine candidate is 65.28% effective 28 days after the dose is given. A Sinopharm subsidiary, the Wuhan Institute of Biologics, says its vaccine candidate is 72.51% effective.

Neither company has publicly released final testing data showing safety and efficacy.


WASHINGTON — Dr. Anthony Fauci says if a coronavirus vaccine is available, regardless of which one, take it.

The top U.S. infectious disease expert told NBC’s “Today” show a third vaccine becoming available “is nothing but good news” and would help control of the pandemic. U.S. regulators announced Wednesday that Johnson & Johnson’s single-dose vaccine offers strong protection against severe COVID-19. It’s expected to be approved soon by the FDA.

Fauci warns people not to hold off on getting the Johnson & Johnson vaccine while waiting for the slightly more effective two-dose Pfizer or Moderna shots.

He says it’s a race “between the virus and getting vaccines into people” and “the longer one waits not getting vaccinated, the better chance the virus has to get a variant or a mutation.”

Fauci says public health officials are always concerned about virus variants and stressed following public health measures of wearing masks and social distancing.

The predominant coronavirus variant in the United States is from Britain. Fauci says the vaccines distributed in the U.S. “clearly can take care of that particular strain.”


NEW YORK — Pfizer announced it has begun studying a third dose of its COVID-19 vaccine, part of a strategy to guard against mutated versions of the coronavirus.

Health authorities say first-generation COVID-19 vaccines still protect against variants that are emerging in different parts of the world. But manufacturers are starting to prepare now in case a more vaccine-resistant mutation comes along.

Pfizer said it will offer a third dose to 144 volunteers, drawing from people who participated in the vaccine’s early-stage U.S. testing last year. It wants to determine if an additional booster shot given six to 12 months after the first two doses would rev up the immune system enough to ward off a mutated virus.

Pfizer and its German partner, BioNTech, also are tweaking their vaccine recipe. The companies are in discussions with U.S. and European regulators about a study to evaluate doses updated to better match variants such as the one first discovered in South Africa.


Featured Article: What is the Fibonacci sequence?

7 Outdoor Recreation Stocks For Growth And Dividends

If American’s liked outdoor activities before, they love them even more now. The COVID-19 pandemic has done many things, and one of them is reinvigorating American’s love of the outdoors. Data from across the industry shows a sustained uptick in revenue that has the entire complex moving higher.

The RV Industry Association, for example, reports shipments of RVs are up greater than 30% in 2020 and are expected to grow another 20% or more in 2021. If data from the two of the industry’s largest manufacturers are any indication, that forecast is very conservative.

And the gains aren’t limited to RVs. Everything that has anything to do with outdoor recreation is booming. Sales at Dicks Sporting Goods, an iconic brand for retail and the outdoors, has seen a sustained 20% increase in revenue since the 2nd quarter shutdowns. If anything, revenue in this sector is being held back by rapidly declining inventory and tight shipping conditions.

The stocks we are about to show all have something in common; the outdoors. Within the group, you will find everything from RVs to Radios and everything in between an outdoor enthusiast could need or want. Some pay dividends and some don’t, but all will deliver solid returns to investors in 2021.

View the "7 Outdoor Recreation Stocks For Growth And Dividends".

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Pfizer (PFE)2.3$38.93+0.9%4.01%25.12Hold$38.57
Johnson & Johnson (JNJ)2.7$162.69+0.3%2.48%25.58Buy$182.62
Compare These Stocks  Add These Stocks to My Watchlist 

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.